Literature DB >> 16793959

Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS.

Djuro Macut1, Svetozar Damjanovic, Dimitrios Panidis, Nikolaos Spanos, Biljana Glisic, Milan Petakov, David Rousso, Anargyros Kourtis, Jelica Bjekic, Natasa Milic.   

Abstract

OBJECTIVE: Women with polycystic ovary syndrome (PCOS) are assumed to be at increased risk for cardiovascular diseases. This study examined the variations in oxidised low-density lipoprotein (OxLDL) concentration in relation to insulin levels in young women with PCOS.
DESIGN: Cross-sectional clinical study in tertiary cares research hospitals. A total of 179 women with PCOS (79 overweight) and 56 age- and body mass index-matched controls were examined.
METHODS: Blood samples were collected in follicular phase of the cycle for the basal glucose, total-, high-density lipoprotein-cholesterol (HDL-C) and LDL-cholesterol, OxLDL, triglycerides, apolipoprotein-A1 (Apo-A1) and B (Apo-B), lipoprotein (a), insulin, testosterone and sex hormone-binding globulin (SHBG). Homeostatic model index (HOMA) and free androgen index (FAI) were determined.
RESULTS: Overweight and normal weight women with PCOS had higher concentrations of OxLDL than their control counterparts (P = 0.007 and 0.003 respectively). Both the basal insulin (P = 0.003) and HOMA values (P < 0.001) were significantly higher in overweight than normal weight patients. Testosterone and FAI were higher in patients than in the respective controls (P < 0.001). The only independent predictor of increased OxLDL concentration in normal weight patients was Apo-B-to-Apo-A1 ratio (P < 0.001, odds ratio (OR) 6.1; 95% confidence interval (CI) 2.3-16.4), while in obese PCOS, it was total cholesterol-to-high-density lipoprotein cholesterol ratio (P < 0.001, OR 2.8; 95% CI 1.6-4.9).
CONCLUSION: Young normal weight and overweight PCOS women have similarly increased OxLDL levels. Our results may indicate the presence of primary alteration in lipid metabolism in patients with PCOS. To answer the question whether the alteration in LDL particle size can by itself pose a higher cardiovascular risk, a careful follow-up of these women is needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793959     DOI: 10.1530/eje.1.02187

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  16 in total

1.  [Disorders of sexual development and identity in childhood and adolescence. Expert meeting in Krefeld, 12 February 2011].

Authors:  S Krege
Journal:  Urologe A       Date:  2011-11       Impact factor: 0.639

Review 2.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

3.  Morelloflavone, a biflavonoid inhibitor of migration-related kinases, ameliorates atherosclerosis in mice.

Authors:  Decha Pinkaew; Nongporn Hutadilok-Towatana; Ba-Bie Teng; Wilawan Mahabusarakam; Ken Fujise
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-04       Impact factor: 4.733

Review 4.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 5.  Cardiovascular risk factors and events in women with androgen excess.

Authors:  D Macut; I B Antić; J Bjekić-Macut
Journal:  J Endocrinol Invest       Date:  2014-11-29       Impact factor: 4.256

Review 6.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.

Authors:  Mark O Goodarzi; Daniel A Dumesic; Gregorio Chazenbalk; Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

7.  Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome.

Authors:  Djuro Macut; Danijela Vojnović Milutinović; Ivana Božić; Gordana Matić; Jelena Brkljačić; Dimitrios Panidis; Milan Petakov; Nikolaos Spanos; Jelica Bjekić; Olivera Stanojlović; Anđela Petrović Milinković; Zoran Radojičić; Svetozar Damjanović
Journal:  Endocrine       Date:  2009-11-17       Impact factor: 3.633

8.  THE EFFECT OF MYOINOSITOL AND METFORMIN ON CARDIOVASCULAR RISK FACTORS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A RANDOMIZED CONTROLLED TRIAL.

Authors:  V Soldat-Stankovic; S Popovic Pejicic; S Stankovic; J Jovanic; J Bjekic-Macut; S Livadas; S Ognjanovic; G Mastorakos; D Micic; D Macut
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

9.  Gonadal soma controls ovarian follicle proliferation through Gsdf in zebrafish.

Authors:  Yi-Lin Yan; Thomas Desvignes; Ruth Bremiller; Catherine Wilson; Danielle Dillon; Samantha High; Bruce Draper; Charles Loren Buck; John Postlethwait
Journal:  Dev Dyn       Date:  2017-09-25       Impact factor: 3.780

10.  Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up.

Authors:  Peggy T Cohen-Kettenis; Sebastiaan E E Schagen; Thomas D Steensma; Annelou L C de Vries; Henriette A Delemarre-van de Waal
Journal:  Arch Sex Behav       Date:  2011-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.